Literature DB >> 24166579

Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.

Miranka Wirth1, Sylvia Villeneuve1, Claudia M Haase2, Cindee M Madison1, Hwamee Oh3, Susan M Landau3, Gil D Rabinovici4, William J Jagust3.   

Abstract

IMPORTANCE: Criteria for preclinical Alzheimer disease (AD) propose β-amyloid (Aβ) plaques to initiate neurodegeneration within AD-affected regions. However, some cognitively normal older individuals harbor neural injury similar to patients with AD, without concurrent Aβ burden. Such findings challenge the proposed sequence and suggest that Aβ-independent precursors underlie AD-typical neurodegenerative patterns. OBJECTIVE To examine relationships between Aβ and non-Aβ factors as well as neurodegeneration within AD regions in cognitively normal older adults. The study quantified neurodegenerative abnormalities using imaging biomarkers and examined cross-sectional relationships with Aβ deposition; white matter lesions (WMLs), a marker of cerebrovascular disease; and cognitive functions. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study in a community-based convenience sample of 72 cognitively normal older individuals (mean [SD] age, 74.9 [5.7] years; 48 women; mean [SD] 17.0 [1.9] years of education) of the Berkeley Aging Cohort. INTERVENTION: Each individual underwent a standardized neuropsychological test session, magnetic resonance imaging, and positron emission tomography scanning. MAIN OUTCOMES AND MEASURES: For each individual, 3 AD-sensitive neurodegeneration biomarkers were measured: hippocampal volume, glucose metabolism, and gray matter thickness, the latter 2 sampled from cortical AD-affected regions. To quantify neurodegenerative abnormalities, each biomarker was age adjusted, dichotomized into a normal or abnormal status (using cutoff thresholds derived from an independent AD sample), and summarized into 0, 1, or more than 1 abnormal neurodegenerative biomarker. Degree and topographic patterns of neurodegenerative abnormalities were assessed and their relationships with cognitive functions, WML volume, and Aβ deposition (quantified using carbon 11-labeled Pittsburgh compound B positron emission tomography).
RESULTS: Of our cognitively normal elderly individuals, 40% (n = 29) displayed at least 1 abnormal neurodegenerative biomarker, 26% (n = 19) of whom had no evidence of elevated Pittsburgh compound B retention. In those people who were classified as having abnormal cortical thickness, degree and topographic specificity of neurodegenerative abnormalities were similar to patients with AD. Accumulation of neurodegenerative abnormalities was related to poor memory and executive functions as well as larger WML volumes but not elevated Pittsburgh compound B retention. CONCLUSIONS AND RELEVANCE: Our study confirms that a substantial proportion of cognitively normal older adults harbor neurodegeneration, without Aβ burden. Associations of neurodegenerative abnormalities with cerebrovascular disease and cognitive performance indicate that neurodegenerative pathology can emerge through non-Aβ pathways within regions most affected by AD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24166579      PMCID: PMC4962545          DOI: 10.1001/jamaneurol.2013.4013

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  34 in total

1.  Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.

Authors:  Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Neuron       Date:  2002-01-31       Impact factor: 17.173

2.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Authors:  E C Mormino; J T Kluth; C M Madison; G D Rabinovici; S L Baker; B L Miller; R A Koeppe; C A Mathis; M W Weiner; W J Jagust
Journal:  Brain       Date:  2008-11-28       Impact factor: 13.501

3.  Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB.

Authors:  S M Resnick; J Sojkova; Y Zhou; Y An; W Ye; D P Holt; R F Dannals; C A Mathis; W E Klunk; L Ferrucci; M A Kraut; D F Wong
Journal:  Neurology       Date:  2010-02-10       Impact factor: 9.910

4.  Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau.

Authors:  Rahul S Desikan; Linda K McEvoy; Wesley K Thompson; Dominic Holland; James B Brewer; Paul S Aisen; Reisa A Sperling; Anders M Dale
Journal:  Arch Neurol       Date:  2012-06

5.  Association of gray matter atrophy with age, β-amyloid, and cognition in aging.

Authors:  Hwamee Oh; Cindee Madison; Sylvia Villeneuve; Candace Markley; William J Jagust
Journal:  Cereb Cortex       Date:  2013-02-06       Impact factor: 5.357

6.  Brain injury biomarkers are not dependent on β-amyloid in normal elderly.

Authors:  David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

7.  Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.

Authors:  Miranka Wirth; Cindee M Madison; Gil D Rabinovici; Hwamee Oh; Susan M Landau; William J Jagust
Journal:  J Neurosci       Date:  2013-03-27       Impact factor: 6.167

8.  The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.

Authors:  Miranka Wirth; Hwamee Oh; Elizabeth C Mormino; Candace Markley; Susan M Landau; William J Jagust
Journal:  Alzheimers Dement       Date:  2013-03-07       Impact factor: 21.566

9.  Brain imaging evidence of preclinical Alzheimer's disease in normal aging.

Authors:  William Jagust; Amy Gitcho; Felice Sun; Beth Kuczynski; Dan Mungas; Mary Haan
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

10.  Amyloid-β associated cortical thinning in clinically normal elderly.

Authors:  J Alex Becker; Trey Hedden; Jeremy Carmasin; Jacqueline Maye; Dorene M Rentz; Deepti Putcha; Bruce Fischl; Douglas N Greve; Gad A Marshall; Stephen Salloway; Donald Marks; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2011-03-17       Impact factor: 10.422

View more
  77 in total

1.  Suspected non-AD pathology in mild cognitive impairment.

Authors:  Laura E M Wisse; Nirali Butala; Sandhitsu R Das; Christos Davatzikos; Bradford C Dickerson; Sanjeev N Vaishnavi; Paul A Yushkevich; David A Wolk
Journal:  Neurobiol Aging       Date:  2015-09-07       Impact factor: 4.673

Review 2.  Suspected non-Alzheimer disease pathophysiology--concept and controversy.

Authors:  Clifford R Jack; David S Knopman; Gaël Chételat; Dennis Dickson; Anne M Fagan; Giovanni B Frisoni; William Jagust; Elizabeth C Mormino; Ronald C Petersen; Reisa A Sperling; Wiesje M van der Flier; Victor L Villemagne; Pieter J Visser; Stephanie J B Vos
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

3.  Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults.

Authors:  Miranka Wirth; Claudia M Haase; Sylvia Villeneuve; Jacob Vogel; William J Jagust
Journal:  Neurobiol Aging       Date:  2014-02-20       Impact factor: 4.673

4.  White matter hyperintensities and imaging patterns of brain ageing in the general population.

Authors:  Mohamad Habes; Guray Erus; Jon B Toledo; Tianhao Zhang; Nick Bryan; Lenore J Launer; Yves Rosseel; Deborah Janowitz; Jimit Doshi; Sandra Van der Auwera; Bettina von Sarnowski; Katrin Hegenscheid; Norbert Hosten; Georg Homuth; Henry Völzke; Ulf Schminke; Wolfgang Hoffmann; Hans J Grabe; Christos Davatzikos
Journal:  Brain       Date:  2016-02-24       Impact factor: 13.501

5.  Alzheimer disease: the landscape of ageing--insights from AD imaging markers.

Authors:  Victor L Villemagne; Colin L Masters
Journal:  Nat Rev Neurol       Date:  2014-11-04       Impact factor: 42.937

6.  Imaging Vascular Disease and Amyloid in the Aging Brain: Implications for Treatment.

Authors:  Sylvia Villeneuve; William J Jagust
Journal:  J Prev Alzheimers Dis       Date:  2015-03

7.  Cerebral white matter free water: A sensitive biomarker of cognition and function.

Authors:  Pauline Maillard; Evan Fletcher; Baljeet Singh; Oliver Martinez; David K Johnson; John M Olichney; Sarah T Farias; Charles DeCarli
Journal:  Neurology       Date:  2019-04-05       Impact factor: 9.910

8.  Temporal Order of Alzheimer's Disease-Related Cognitive Marker Changes in BLSA and WRAP Longitudinal Studies.

Authors:  Murat Bilgel; Rebecca L Koscik; Yang An; Jerry L Prince; Susan M Resnick; Sterling C Johnson; Bruno M Jedynak
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression.

Authors:  Anna Caroli; Annapaola Prestia; Samantha Galluzzi; Clarissa Ferrari; Wiesje M van der Flier; Rik Ossenkoppele; Bart Van Berckel; Frederik Barkhof; Charlotte Teunissen; Anders E Wall; Stephen F Carter; Michael Schöll; Il Han Choo; Timo Grimmer; Alberto Redolfi; Agneta Nordberg; Philip Scheltens; Alexander Drzezga; Giovanni B Frisoni
Journal:  Neurology       Date:  2015-01-07       Impact factor: 9.910

Review 10.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.